Press-release for stocks for TAK

Prices are updated after-hours

Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

symbols : TAK crawled time : 18:00

save search

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Published: 2024-03-26 (Crawled : 18:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M

|

Health Technology

| -7.07% | O: 1.84% H: 0.24% C: -0.14%
adzynma japan takeda approval injection

FRUZAQLA™ (fruquintinib) Now Available from Onco360 for the Treatment of Adult Patients with Metastatic Colorectal Cancer (mCRC)
Published: 2023-11-21 (Crawled : 18:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M

|

Health Technology

| -6.14% | O: 0.07% H: 0.57% C: 0.0%
cancer treatment

Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
Published: 2023-11-02 (Crawled : 18:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M

|

Health Technology

| -3.66% | O: 1.03% H: 0.73% C: 0.58%
NVS | $92.57 -0.55% 0.0% 910K

|

Health Technology

| -1.25% | O: -1.09% H: 1.03% C: 0.91%
XNCR | $18.98 -0.47% -0.47% 470K

|

Health Technology

| 9.16% | O: 1.32% H: 0.45% C: -1.19%
MOR | $18.02 -0.11% -0.11% 590K

|

Health Technology

| 122.29% | O: 2.22% H: 0.6% C: -9.4%
INCY | $52.82 0.19% 0.19% 1.8M

|

Health Technology

| -2.85% | O: -0.28% H: 1.0% C: -0.46%
presentation meeting

Kadcyla Leads the Global Antibody Drug Conjugates Market with Extensive Use in Breast Cancer Treatment
Published: 2023-11-01 (Crawled : 18:00) - prnewswire.com
ALPMY | $9.46 -1.11% 500K

|

| -23.18% | O: -1.46% H: 3.67% C: 3.26%
ZYME | $8.68 -1.92% -1.96% 730K

|

Health Technology

| 26.07% | O: 1.14% H: 0.42% C: -0.7%
TAK | News | $13.16 0.08% 0.0% 1.3M

|

Health Technology

| -3.66% | O: 1.03% H: 0.73% C: 0.58%
ADCT | $4.76 -4.03% 0.0% 280K

|

Health Technology

| 609.28% | O: -0.16% H: 6.42% C: 4.49%
ABBV | News | $164.66 0.25% -0.15% 4.5M

|

Health Technology

| 15.93% | O: -0.86% H: 0.0% C: 0.0%
STRO M | $3.76 -1.05% -1.06% 770K

|

Health Technology

| 47.29% | O: 0.39% H: 3.86% C: 3.86%
IMGN | $31.23 0.03% 49M

|

Health Technology

| 109.1% | O: 5.09% H: 5.48% C: -1.27%
GILD | News | $66.16 -1.15% -1.16% 6.4M

|

Health Technology

| -16.57% | O: -0.47% H: 1.88% C: 1.78%
EXEL | $22.47 -1.75% -1.78% 2.6M

|

Health Technology

| 9.54% | O: -2.62% H: 1.17% C: -1.66%
drug antibody breast cancer treatment global market

Global Gaucher's Disease Treatment Market Research Report 2023: Emerging Therapies, Clinical Trials, Treatments, Current Scenario Evaluation, Patient Profile
Published: 2023-05-10 (Crawled : 18:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K

|

Health Technology

| 8.88% | O: 0.92% H: 0.0% C: 0.0%
TAK | News | $13.16 0.08% 0.0% 1.3M

|

Health Technology

| -22.56% | O: -1.83% H: 0.12% C: -3.06%
NVS | $92.57 -0.55% 0.0% 910K

|

Health Technology

| -10.18% | O: -0.4% H: 0.34% C: 0.19%
JNJ | News | $145.74 0.67% 0.0% 9.3M

|

Health Technology

| -10.33% | O: 0.11% H: 0.22% C: -0.52%
ABT | News | $105.27 -0.6% -0.15% 7.3M

|

Health Technology

| -3.88% | O: -0.57% H: 0.37% C: -0.01%
SNY | News | $45.395 -1.55% -1.58% 4.4M

|

Health Technology

| -15.88% | O: -0.28% H: 0.0% C: 0.0%
disease report treatment research global market

Antacids Global Market Report 2023
Published: 2023-02-20 (Crawled : 18:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510

|

Health Technology

| Email alert Add to watchlist
AZN | $68.36 -0.25% -0.25% 4M

|

Health Technology

| Email alert Add to watchlist
AZNCF | $140.15 -4.19% 560

|

Health Technology

| Email alert Add to watchlist
TAK | News | $13.16 0.08% 0.0% 1.3M

|

Health Technology

| Email alert Add to watchlist
ABT | News | $105.27 -0.6% -0.15% 7.3M

|

Health Technology

| Email alert Add to watchlist
GSK | $39.27 -0.83% 0.01% 2.2M

|

Health Technology

| Email alert Add to watchlist
global report market

Insights on the Insomnia Global Market to 2028 - Featuring Eisai, Takeda Pharmaceutical, Vanda Pharmaceuticals and Cadila Healthcare Among Others
Published: 2023-01-25 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K

|

Health Technology

| -5.73% | O: -0.92% H: 1.41% C: 1.41%
TAK | News | $13.16 0.08% 0.0% 1.3M

|

Health Technology

| -18.47% | O: 0.25% H: 0.53% C: 0.43%
PFE A | $25.39 -0.12% -0.12% 36M

|

Health Technology

| -43.14% | O: 0.72% H: 0.18% C: 0.09%
SNY | News | $45.395 -1.55% -1.58% 4.4M

|

Health Technology

| -6.16% | O: 0.39% H: 0.0% C: 0.0%
pharmaceuticals global market

Global Rare Disease Drugs Market Report 2022-2027: Increasing Focus on Research Activities and Development of Novel Therapeutic Drugs to Facilitate Future Growth
Published: 2022-12-15 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K

|

Health Technology

| -1.85% | O: -0.85% H: 0.0% C: 0.0%
TAK | News | $13.16 0.08% 0.0% 1.3M

|

Health Technology

| -14.67% | O: -0.71% H: 0.07% C: -1.05%
NVS | $92.57 -0.55% 0.0% 910K

|

Health Technology

| 0.59% | O: -0.71% H: 0.08% C: -1.07%
ABBV | News | $164.66 0.25% -0.15% 4.5M

|

Health Technology

| 0.18% | O: -0.59% H: 0.44% C: -0.48%
SNY | News | $45.395 -1.55% -1.58% 4.4M

|

Health Technology

| -4.39% | O: 0.04% H: 0.0% C: 0.0%
rare research global disease report growth market

8 MM Ulcerative Colitis Market Forecasts, Epidemiology & Pipeline Analysis 2022-2027: Novel Emerging Drugs will Shift the Inflammatory Bowel Disease (IBD) Treatment Paradigm
Published: 2022-09-02 (Crawled : 18:00) - prnewswire.com
ARVL | News | $0.49 0.37% 2.5M

|

| -47.61% | O: 1.43% H: 0.0% C: 0.0%
TAK | News | $13.16 0.08% 0.0% 1.3M

|

Health Technology

| -4.29% | O: -0.15% H: 0.29% C: -1.02%
PFE A | $25.39 -0.12% -0.12% 36M

|

Health Technology

| -45.49% | O: 0.24% H: 0.13% C: -2.23%
NVS | $92.57 -0.55% 0.0% 910K

|

Health Technology

| 15.87% | O: 0.21% H: 0.86% C: -0.99%
JNJ | News | $145.74 0.67% 0.0% 9.3M

|

Health Technology

| -10.34% | O: 2.55% H: 0.0% C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M

|

Health Technology

| 142.87% | O: 0.32% H: 0.04% C: -2.83%
BHC | $8.6 -0.69% 0.0% 2.1M

|

Health Technology

| 32.63% | O: 1.06% H: 1.35% C: -3.15%
treatment disease market ulcerative colitis

Irritable Bowel Syndrome Treatment Market to Surpass US$ 3,902.9 Million by 2030 - Coherent Market Insights
Published: 2022-06-24 (Crawled : 18:00) - prnewswire.com
ALPMF | $9.594 43.47% 2.2K

|

Health Technology

| -39.1% | O: 0.99% H: 0.0% C: -0.5%
NVSEF | $93.6375 6.88% 82K

|

Health Technology

| 42.6% | O: 6.71% H: 0.0% C: -0.1%
ALPMY | $9.46 -1.11% 500K

|

| -41.33% | O: 4.33% H: 0.0% C: -2.44%
TAK | News | $13.16 0.08% 0.0% 1.3M

|

Health Technology

| -4.22% | O: 0.36% H: 0.0% C: 0.0%
NVS | $92.57 -0.55% 0.0% 910K

|

Health Technology

| 14.09% | O: 2.38% H: 0.0% C: 0.0%
BHC | $8.6 -0.69% 0.0% 2.1M

|

Health Technology

| 20.22% | O: 5.78% H: 13.91% C: 13.78%
ABBV | News | $164.66 0.25% -0.15% 4.5M

|

Health Technology

| 11.29% | O: 1.57% H: 0.0% C: 0.0%
IRWD | $7.59 -0.78% -0.79% 3.6M

|

Health Technology

| -31.22% | O: 0.27% H: 2.08% C: 1.99%
treatment market

Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published: 2022-05-03 (Crawled : 18:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M

|

Health Technology

| -9.25% | O: 0.41% H: 0.0% C: 0.0%
BMY | $48.3 0.96% -0.1% 11M

|

Health Technology

| -35.67% | O: 0.36% H: 0.0% C: 0.0%
EXEL | $22.47 -1.75% -1.78% 2.6M

|

Health Technology

| 1.61% | O: 0.09% H: 1.54% C: -0.44%
cabometyx approval cancer

Global Lupus Therapeutic Market to Surpass US$ 5,408.1 Million by 2030, Says Coherent Market Insights
Published: 2022-03-16 (Crawled : 18:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510

|

Health Technology

| -3.16% | O: -0.46% H: 3.49% C: 3.49%
NVSEF | $93.6375 6.88% 82K

|

Health Technology

| 15.32% | O: 2.25% H: 0.0% C: 0.0%
UCBJY | $64.07 -4.38% 72K

|

| 16.13% | O: 1.41% H: 2.33% C: 0.04%
TAK | News | $13.16 0.08% 0.0% 1.3M

|

Health Technology

| -9.25% | O: 2.07% H: 1.62% C: 1.56%
NVS | $92.57 -0.55% 0.0% 910K

|

Health Technology

| 10.49% | O: 0.74% H: 0.0% C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M

|

Health Technology

| -5.04% | O: 0.41% H: 0.0% C: 0.0%
BMY | $48.3 0.96% -0.1% 11M

|

Health Technology

| -30.75% | O: 0.26% H: 0.31% C: -0.39%
SNY | News | $45.395 -1.55% -1.58% 4.4M

|

Health Technology

| -11.53% | O: 0.82% H: 0.0% C: 0.0%
AUPH | $4.81 -2.04% -2.08% 2.1M

|

Health Technology

| -54.15% | O: 0.95% H: 6.23% C: 5.19%
AMGN | $262.77 -0.49% -0.49% 2M

|

Health Technology

| 14.41% | O: 0.41% H: 0.0% C: -0.37%
lupus market

Worldwide Budesonide Inhaler Industry to 2026 - Further Innovation in Inhaled Therapy for Airways Disease Presents Opportunities
Published: 2021-09-30 (Crawled : 18:00) - prnewswire.com
AZNCF | $140.15 -4.19% 560

|

Health Technology

| 11.27% | O: -1.61% H: 0.07% C: -1.56%
VTRS | $11.11 0.09% 0.09% 3.5M

|

Health Technology

| -17.93% | O: 0.07% H: 1.22% C: 0.29%
TAK | News | $13.16 0.08% 0.0% 1.3M

|

Health Technology

| -19.72% | O: -0.15% H: 0.0% C: 0.0%
ABT | News | $105.27 -0.6% -0.15% 7.3M

|

Health Technology

| -9.93% | O: 0.06% H: 0.19% C: -0.84%
AZN | $68.36 -0.25% -0.25% 4M

|

Health Technology

| 13.66% | O: -1.28% H: 0.0% C: 0.0%
disease therapy

Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021
Published: 2021-09-20 (Crawled : 18:00) - biospace.com/
TAK | News | $13.16 0.08% 0.0% 1.3M

|

Health Technology

| -23.5% | O: -1.22% H: 0.0% C: 0.0%
EXEL | $22.47 -1.75% -1.78% 2.6M

|

Health Technology

| 12.78% | O: -1.64% H: 1.34% C: -1.29%
results cancer phase 3 trial

Pharmaceutical Executive® APEX Awards Announces 2021 Finalists
Published: 2021-07-08 (Crawled : 18:00) - prnewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M

|

Health Technology

| -20.93% | O: -0.9% H: 0.12% C: -0.12%
TXMD | $1.98 4.76% 4.55% 5.7K

|

Health Technology

| 70.27% | O: -1.8% H: 3.67% C: 2.75%
GILD | News | $66.16 -1.15% -1.16% 6.4M

|

Health Technology

| -2.14% | O: -0.45% H: 0.39% C: -0.54%
ATNX | $0.2031 -7.78% 1.9M

|

Health Technology

| -94.96% | O: -1.24% H: 7.04% C: 6.78%
APLS | $47.51 -1.08% -1.09% 1.9M

|

Health Technology

| -29.84% | O: -3.01% H: 3.4% C: -0.35%
AMGN | $262.77 -0.49% -0.49% 2M

|

Health Technology

| 8.93% | O: 0.42% H: 1.01% C: 0.02%
awards

Global Medical Enzyme Technology Market (2021 to 2028) - COVID-19 Impact and Analysis
Published: 2021-05-19 (Crawled : 18:00) - prnewswire.com
TMO | News | $541.52 -1.05% 0.61% 2.1M

|

Health Technology

| 17.24% | O: -0.6% H: 1.38% C: 1.12%
TAK | News | $13.16 0.08% 0.0% 1.3M

|

Health Technology

| -23.72% | O: -0.52% H: 0.35% C: -0.06%
A | $132.44 -1.57% -0.36% 1.9M

|

Health Technology

| 6.25% | O: -0.89% H: 2.1% C: 2.05%
covid technology covid-19

Gainers vs Losers

64%

36%

Top 10 Gainers

AGBA | News | $1.02 155.0% 57.94% 120M

|

ZCMD | $2.86 108.76% 52.1% 2.3M

|

Commercial Services

INVO | $1.555 104.6% 51.13% 5M

|

Health Technology

ISPC | $0.437 105.16% 49.53% 37M

|

Professional, Scientific, and T...

WLGS | News | $0.92 84.0% 45.65% 1.6M

|

OST | $0.499 21.38% 45.26% 1.9M

|

XPON | News | $3.1 60.62% 37.74% 17M

|

TIRX | $0.7 44.39% 30.74% 58M

|

BNTC | News | $6.92 44.17% 30.64% 3.5M

|

Health Technology

GGE | $0.035 19.86% 29.3% 64M

|

Your saved searches

Save your searches and get alerts when important news are released.